Durable Responses at ≥ 12 Months With Zola-cel in Severe Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Translational Findings From the Full Phase 1 Breakfree-1 Cohort (ACR Convergence 2026) - Oct 16, 2026 - Abstract #LB04; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; P1, P2 | "A single zola-cel infusion showed rapid and sustained clinical benefits at ≥1 yr of F/U, with most pts remaining off disease-directed ISTs. Predominant naive B cell repopulation and sustained IFN gene signature suppression even after B cell return are consistent with biological changes that may reflect a durable immune reset. Inflammatory events were mostly low-grade, transient, and resolved without long-term clinical sequelae."
Clinical • Late-breaking abstract • P1 data • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
|
|
Emily Littlejohn 1; Georg Schett 2; Amit Saxena 3; Margrit Wiesendanger 4; Ellen De Langhe 5; Anca Askanase 6; Elana Bernstein 7; Neil Kramer 8; Philip Mease 9; Vikas Majithia 10; Brandon M. Law 11; Ryan Yoast 11; San-San Ou 11; Griff McTume 11; Melissa Harnois 11; Jerill Thorpe 11; Jasmine Saini 11; Sharmila Das 11; Ashley Koegel 11; and David Simon 12
|